GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Panbela Therapeutics Inc (OTCPK:PBLA) » Definitions » Volatility

Panbela Therapeutics (Panbela Therapeutics) Volatility : 140.00% (As of May. 25, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Panbela Therapeutics Volatility?

Volatility is a statistical measure of the dispersion of returns for a given security or market index, it shows how the price swings around its mean. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year. In most cases, the higher the volatility, the riskier the security.

As of today (2024-05-25), Panbela Therapeutics's Volatility is 140.00%.


Competitive Comparison of Panbela Therapeutics's Volatility

For the Biotechnology subindustry, Panbela Therapeutics's Volatility, along with its competitors' market caps and Volatility data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Panbela Therapeutics's Volatility Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Panbela Therapeutics's Volatility distribution charts can be found below:

* The bar in red indicates where Panbela Therapeutics's Volatility falls into.



Panbela Therapeutics  (OTCPK:PBLA) Volatility Calculation

The annualized volatility is calculated as following:

σA=σM * 12
= 1/(n-1) ∑(Ri - R')^2 * 12

Where: σM is the monthly volatility, n is the number of months in the period, Ri is the security's historical monthly returns and R' is the arithmetic mean of monthly returns.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Panbela Therapeutics  (OTCPK:PBLA) Volatility Explanation

Volatility is a statistical measure of the dispersion of returns for a given security or market index. It’s often measured as standard deviation or variance of historical returns over a certain period. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year.

Volatility reflects the uncertainty or risk of a security’s value. Generally speaking, a higher volatility suggests a higher risk, because it implies a wider fluctuation around average price. This means the price of the security can change dramatically in either direction within a short period. Conversely, a lower volatility means that the security's price is more steady, which suggests a lower risk.

Another measurement of relative volatility is Beta. Beta is a measure of systematic risk of a security or a portfolio in comparison to the market as a whole. Beta is usually compared to 1. A beta of greater than 1 indicates that the security's price will be more volatile than the market.


Panbela Therapeutics Volatility Related Terms

Thank you for viewing the detailed overview of Panbela Therapeutics's Volatility provided by GuruFocus.com. Please click on the following links to see related term pages.


Panbela Therapeutics (Panbela Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
712 Vista Boulevard, Suite 305, Waconia, MN, USA, 55387
Panbela Therapeutics Inc is a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The Company's pipeline assets are ivospemin (SBP-101), FlynpoviTM (eflornithine (CPP-1X) and sulindac), and eflornithine (CPP-1X), which provide a multi-targeted approach to reset dysregulated biology present in many types of diseases such as cancer and autoimmunity.
Executives
Jennifer K. Simpson director, officer: President and CEO C/O DELCATH SYSTEMS, INC., 810 SEVENTH AVENUE, SUITE 3505, NEW YORK NY 10019
Susan Horvath officer: V.P. of Finance & CFO 4645 ITHACA LANE, PLYMOUTH MN 55446
Jeffrey E. Jacob director 712 VISTA BLVD #305, WACONIA MN 55387
Daniel Donovan director 712 VISTA BLVD #305, WACONIA MN 55387
Paul W. Schaffer director 712 VISTA BLVD #305, WACONIA MN 55387
Arthur Fratamico director C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
Ryan R. Gilbertson 2012 Irrevocable Trust 10 percent owner 1000 PARKER'S LAKE RD, WAYZATA MN 55391
Ryan Randall Gilbertson 10 percent owner 130 LAKE ST. WEST, WAYZATA MN 55391
Donald Robert Schemel director 712 VISTA BLVD #305, WACONIA MN 55387
Dalvir S Gill director 712 VISTA BLVD SUITE 305, WACONIA MN 55387
Scott Kellen officer: Chief Financial Officer 3405 ANNAPOLIS LANE, SUITE 200, MINNEAPOLIS MN 55447
Jeffrey S Mathiesen director 43334 SEVEN MILE RD., SUITE 1000, NORTHVILLE MI 48167
Paulson J Robert Jr director
Daniel E. Ryweck officer: Chief Financial Officer 712 VISTA BLVD #305, WACONIA MN 55387
Michael T. Cullen director 712 VISTA BLVD, #305, WACONIA MN 55387

Panbela Therapeutics (Panbela Therapeutics) Headlines

From GuruFocus

Panbela Announces 1-for-30 Reverse Stock Split Effective June 1, 2023

By sperokesalga sperokesalga 05-31-2023

Panbela Announces Pricing of Approximately $15 Million Public Offering

By Stock market mentor Stock market mentor 01-26-2023